Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
4 participants
INTERVENTIONAL
2010-06-30
2011-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies
NCT02503033
A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies
NCT04861779
A Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies
NCT04865458
IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
NCT02028039
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML
NCT04842370
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IPI-493
IPI-493
Capsules, ascending dose, multiple schedules
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IPI-493
Capsules, ascending dose, multiple schedules
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ECOG 0-1
* confirmed hematological malignancy
* refractory to available therapy or for which no therapy is available
* adequate hepatic, renal function
Exclusion Criteria
* prolonged QT interval
* significant GI/liver disease
* other serious concurrent illness or medical condition
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Infinity Pharmaceuticals, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Ross, M.D.
Role: STUDY_DIRECTOR
Infinity Pharmaceuticals, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Johns Hopkins Sidney Kimmel Cancer Center
Baltimore, Maryland, United States
Weill Cornell Cancer Center
New York, New York, United States
M.D. Anderson Cancer Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IPI-493-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.